A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies

摘要

Molecular targeted therapies have changed the landscape of cancer research. Agonistic monoclonal antibodiesn(MoAbs) targeting TRAIL-death receptors (TRAIL-Rs) have been developed and currently used in clinical trials. Bindingnof such antibodies to TRAIL-R1 and TRAIL-R2 results in death inducing signalling complex (DISC) formation and inductionnof apoptosis, which represents a natural mechanism of cell growth control and an ideal target for drug development.nThese novel fully humanized compounds have been associated with conventional chemotherapy in the treatment ofnadvanced solid malignancies, including different types of lymphoma. Here we outline the rationale and potential of a newnmolecular-based strategy combining agonistic anti-TRAIL-death receptor monoclonal antibodies plus the pioneer of thennew biological frontiers of cancer therapy: rituximab.